<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114387</url>
  </required_header>
  <id_info>
    <org_study_id>AG0023</org_study_id>
    <secondary_id>R01AG013860</secondary_id>
    <nct_id>NCT00114387</nct_id>
  </id_info>
  <brief_title>VEAPS: Vitamin E Atherosclerosis Prevention Study</brief_title>
  <official_title>VEAPS: Vitamin E Atherosclerosis Prevention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol)&#xD;
      supplementation will reduce the progression of early atherosclerosis in healthy individuals&#xD;
      over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or&#xD;
      equal to 130mg/dL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis to be tested is that vitamin E supplementation of 400 IU/day exerts&#xD;
      positive arterial wall effects by reducing progression of early atherosclerosis in healthy&#xD;
      individuals 40 years old or older without clinical evidence of cardiovascular disease (CVD).&#xD;
      Ultrasonography will be used to measure the rate of change of the distal common carotid&#xD;
      artery (CCA) far wall intima-media thickness (IMT). The beneficial effects of vitamin E&#xD;
      supplementation are expected to occur with or without a change in LDL-C levels.&#xD;
&#xD;
      A total of 353 men and women will be recruited for the three-year trial. Participants will be&#xD;
      randomized into a treatment group to receive either vitamin E (DL-alpha-tocopherol) 400&#xD;
      IU/day or a placebo. The ultrasound measurement of CCA IMT will be repeated every six months&#xD;
      for two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">September 2000</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of the distal common carotid artery (CCA) far wall intima-media thickness (IMT)</measure>
  </primary_outcome>
  <enrollment>353</enrollment>
  <condition>Atherosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DL-alpha-tocopherol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  40 years or older&#xD;
&#xD;
          -  Fasting LDL-C level 130 mg/dL or greater, TG (triglyceride) levels 500mg/dL or lower&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical signs or symptoms of cardiovascular disease (CVD)&#xD;
&#xD;
          -  Diabetes mellitus or fasting serum glucose 140mg/dL or greater&#xD;
&#xD;
          -  Regular vitamin E supplementation for more than 1 year&#xD;
&#xD;
          -  Lipid standardized plasma vitamin E levels greater than 35 micromoles per liter&#xD;
             (Î¼mol/L)&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic blood pressure 100 mmHg or greater)&#xD;
&#xD;
          -  Thyroid disease (untreated)&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine greater than 2.5 mg/dL)&#xD;
&#xD;
          -  Life threatening disease with prognosis less than 5 years&#xD;
&#xD;
          -  Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4&#xD;
             oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard N. Hodis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen SP; VEAPS Research Group. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002 Sep 17;106(12):1453-9.</citation>
    <PMID>12234947</PMID>
  </results_reference>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>June 14, 2005</study_first_submitted>
  <study_first_submitted_qc>June 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2005</study_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2009</last_update_posted>
  <keyword>vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

